The Franklin’s mission is dedicated to developing disruptive new technologies to tackle major challenges in life sciences, better ensuring UK pandemic preparedness and accelerating the discovery of new treatments for chronic diseases affecting millions of people around the world, such as dementia.
Supporting the Franklin’s ambition to turn discovery into impact, the Translation and Enterprise Advisory Board (TEAB) will play a central role in guiding invention and translation. TEAB will be chaired by Jo Pisani, a national leader in science entrepreneurship with 30 years in industry and consulting, including leading PwC’s UK Pharmaceutical and Life Sciences practice. She is on the board of translational science funders and delivery organisations including LifeArc, UK Dementia Research Institute and Beacon for Rare Diseases (FindACure), and chairs both the MedCity Advisory Board and Birmingham’s Precision Health Technology Accelerator.
Professor Paul Matthews, Director of the Rosalind Franklin Institute, said:
Now is the right time for the Franklin to build on the creativity and expertise of its scientists, translating their discoveries to invent methods, tools and products that can be scaled through commercial partnerships and spin outs to bring the benefits of its science to people who need them.
